Featured
Last news
David's Bridal Debuts Vera Wang Bride Collection at New York Bridal Fashion Week
Reimagined for the Modern Bride, The Collection Takes Inspiration from Some of Vera Wang's Timeless Bridal Designs, Available Now Online & In-Stores June 30th
Most Men Wait Years to See a Specialist - At Starke Medical Group, They Can Reach One Right Now
Houston Physician Dr. Nathan Starke Launches a Concierge Practice Built Around House Calls, Telemedicine, 24/7 Direct Access for Patients of All Genders - No Waiting Rooms. Ever.
Food Safety Summit Announces Addition of FSPCA Food Traceability Rule Participant Course to 2026 Program
Late-Breaking Training Opportunity Supports Industry Preparation for FDA Traceability Rule Compliance
Payer-to-Payer API Reality Gap Report Finds Most Exchanged Data Still Fails at the Point of Operational Use
Black Book Research, in its 2026 research series on payer IT, software, and services, reports that data usability, workflow activation, identity confidence, and provenance gaps, rather than transport alone, now define payer-to-payer interoperability success or failure.
Evviva Trattoria Sets The Table in Concord with Fresh, Italian-Inspired Fare
Modern Italian Restaurant Opens April 8 in New Hampshire's Capital City
Kultura Brands, Inc. (OTCID:LTNC) Reports Strong Early Sell-Through in Georgia and Expands into Northeast with Massachusetts Launch
LAKEWOOD, CO / ACCESS Newswire / April 7, 2026 / Kultura Brands, Inc. (OTCID:LTNC) ("Kultura Brands," "Kultura," or the "Company")formerly Labor Smart Inc., a publicly traded consumer platform focused on scaling high-growth beverage and lifestyle brands, today provided an operational update highlighting continued commercial momentum for Adios Spirits and the Company's expansion into the Northeast.
T-REX Acquisition Corp. (OTCQB:TRXA) Completes Strategic Refinancing of Orofino, Idaho Data Center
Positions Company for Expansion Across Crypto Infrastructure, Mining Operations, and Modular Deployment Solutions
Remergify, Farrington Capital Group, and Near Infrared Imaging Announce Global Partnership to Launch "AI Buddy" Medical Diagnostic Suite
MIAMI, FL / ACCESS Newswire / April 7, 2026 / Remergify, Farrington Capital Group (FCG), and Near Infrared Imaging, LLC (NII) today announced the formalization of a landmark Strategic Management and Development Agreement. This worldwide partnership integrates advanced near-infrared imaging hardware with proprietary artificial intelligence to deliver high-quality, affordable medical diagnostic solutions to the global community.
Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval
The number of oral weight-loss / diabetes drug treatments is expanding, increasing demand for the reduction of side effects
Arthritis Foundation Invites the Public to Join Green Heart Fridays During Arthritis Awareness Month
Nationwide Free Art Activation Returns for Arthritis Awareness Month
Dolphin Subsidiaries The Door and Shore Fire Media Partner on Launch of Pawn Shop, a New Sports-Driven Hospitality Concept
Opening June 2026 in Los Angeles ahead of the World Cup, Pawn Shop blends community-driven sports culture with elevated dining and luxury viewing
New to The Street Resigns Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) to Continue Long-Form Interview Series, Outdoor Media Campaigns and Accredited Investor Events
Three Consecutive Years of Ongoing Predictable Media™ Partnership
Stemtech Secures Inventory Funding
NAPLES, FL / ACCESS Newswire / April 7, 2026 / Stemtech Corporation, the global leader and pioneer in stem cell nutrition, secures funding for production of $2.5 Million of Inventory to protect against supply chain interruptions.
Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides
SHELTON, CT / ACCESS Newswire / April 7, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced today that it has filed an application for "Rare Pediatric Disease Drug" Designation (RPDD) for NV-387 as a Treatment for Measles with the US FDA Office of Orphan Products Development (OOPD). This RPDD application is expected to be joined together with the Orphan Drug Designation application for NV-387 as a Treatment for Measles that the Company has filed in February, 2026.
New to The Street Signs Medicus Pharma Ltd. (NASDAQ:MDCX) to Transformational 12-Part National Media Series Highlighting SkinJect(TM) and Teverelix(R) Platforms
NEW YORK CITY, NY / ACCESS Newswire / April 7, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX), a precision-guided biotech and life sciences company advancing innovative therapeutic platforms, has entered into a 12-part, one-year strategic media agreement with New to The Street to expand its national and international visibility across television, digital, and outdoor platforms.
Jaguar Health Reports 2025 Financials
Net revenue increase of 5% in Q4 2025 vs. Q3 2025Jaguar received an up-front payment of $16Mof non-dilutive capital in January 2026 upon entering U.S. license agreement with Future Pak for Mytesi® and Canalevia®-CA1 - Jaguar's commercialized crofelemer drugs - with an additional $2 million due upon completion of post-closing conditions; and has received $3.0 of up to $20 million in milestone payments and other future paymentsAgreement with Future Pak is fully aligned with Jaguar's strategy to concentrate crofelemer development efforts on human rare-disease intestinal failure indications moving forwardJaguar will appeal Nasdaq's March 5, 2026 noncompliance determination related to Nasdaq Listing Rule 5550(a)(2) at a hearing on April 7, 2026; delisting is stayed pending the panel's final decisionREMINDER: Friday, April 10, Jaguar to host investor webcast at 8:30 a.m. Eastern regarding Q4 2025 financials and company updates; Click here to register
Innovation Beverage Group and BlockFuel Energy Provide Operational Update on Well Reactivation, Initial Production and Development Progress
SYDNEY, AU / ACCESS Newswire / April 7, 2026 / Innovation Beverage Group Ltd ("IBG" or the "Company") (Nasdaq:IBG), an innovative developer, manufacturer, and marketer of a growing beverage portfolio of 60 formulations across 13 alcoholic and non-alcoholic brands, along with its proposed merger partner BlockFuel Energy ("BFE"), a Texas-based energy corporation, today provided an operational update on its ongoing well reactivation program, initial production performance, and development planning activities across its Central Oklahoma asset base.
Medical Care Technologies Builds on Strong Annual Results as Snapshot Recipes iHeart Podcast Campaign Goes Live Today
MESA, AZ / ACCESS Newswire / April 7, 2026 / Medical Care Technologies Inc. (OTC PINK:MDCE) ("the Company") today provided an update as its previously announced podcast marketing campaign for Snapshot Recipes officially goes live today, marking a continued step forward following the Company's recently reported strong annual results.
Ensysce Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain Programs
~Continued funding underscores investor confidence and supports advancement of abuse- and overdose-resistant analgesics~
InterContinental Hotels Group PLC Announces Transaction in Own Shares - April 07
LONDON, UK / ACCESS Newswire / April 7, 2026 / The Company announces that on 02 April 2026 it purchased the following number of its ordinary shares of 20340/399 pence each through Goldman Sachs International ("GSI") on the London Stock Exchange in accordance with the authority granted by shareholders at the Company's Annual General Meeting on 8 May 2025 (the "Purchase"). The Purchase was effected pursuant to instructions issued by the Company on 17 February 2026, as announced on 17 February 2026.
BioNxt Secures Unitary European Patent for Sublingual Cladribine ODF Platform Across 18 Countries
VANCOUVER, BC / ACCESS Newswire / April 7, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce the official registration of unitary effect for European Patent No. 4539857 covering the Company's proprietary sublingual cladribine oral thin film (ODF) platform.
Trump says Iran ceasefire proposal 'not good enough'
US President Donald Trump said Monday that a proposed 45-day ceasefire with Iran was a "very significant step" but "not good enough" for him to sign, as Iranian officials vowed to keep fighting.
In El Salvador's mass trials, 'the innocent pay for the guilty'
Wearing white uniforms, their heads shaved, rows of bewildered-looking men are beamed by video link from prisons across El Salvador into a courtroom conducting a mass trial of alleged gang members.
Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026
CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010, its investigational seasonal influenza vaccine, and for mRESVIA® (mRNA-1345), its mRNA respiratory syncytial virus (RSV) vaccine, at the 2026 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Munich, Germany, on April 17-21, 2026.
NX Development Corp Submits Supplemental New Drug Application to FDA for MEN-301 Study
LEXINGTON, KY / ACCESS Newswire / April 6, 2026 / NX Development Corp (NXDC) is pleased to announce that after successfully completing the data analysis of our MEN-301 Study of the use of Gleolan® (aminolevulinic acid HCl) to enhance visualization of newly diagnosed or recurrent meningioma, we have submitted these data to the FDA for review as part of an efficacy supplement to our Gleolan New Drug Application (NDA).
Emerging Growth Research Reiterates Buy-Extended Rating on SBC Medical Group Holdings, Inc. with $9.00 Price Target Following Q4:25 Quarterly Update
NEW YORK CITY, NY / ACCESS Newswire / April 6, 2026 / Emerging Growth Research today announced the release of its Quarterly Update Report on SBC Medical Group Holdings, Inc. (Nasdaq:SBC), reiterating a Buy-Extended rating and maintaining its 12-month price target of $9.00, representing potential upside from the Company's closing price of $4.47 on April 3, 2026.
Revolutionary Cancer Company Oncosure Testing Announces New Non-Executive Advisory Board
HHS AND CMS HEALTHCARE ADVISORY BOARD COMMITTEE MEMBER ELIZABETH FAGO APPOINTED TO CHAIR ONCOSURE NON-EXECUTIVE ADVISORY BOARD
MyPlanAdvocate Rebrands as MPA and Integrates HealthyLabs, Bringing AI-Powered Performance Marketing In-House
New identity reflects the company's evolution into a platform for licensed professionals; HealthyLabs acquisition adds AI-driven lead generation, multi-channel campaign management, and real-time routing to MPA's capabilities
TrustNFT Releases White Paper on Corporate Costs of Email Impersonation, Documenting $2.9 Billion in Annual Losses and Growing Brand Liability Risk
New research details financial, reputational, and regulatory damage facing utilities, banks, and insurers whose brands are weaponized by criminal phishing operations
Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board
SAN DIEGO, CA / ACCESS Newswire / April 6, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today announced formation of an Acute Kidney Injury (AKI) Advisory Board for the upcoming Phase 2/3 AKI clinical trial. This distinguished panel brings together internationally recognized Nephrologists and Critical Care Physicians who will guide the company's clinical strategy, monitor progress, and ensure the initiative achieves the goal of improving patient care by advancing Gemini for the treatment of AKI. Their collective insight will help inform the most pertinent study design to best address the significant unmet medical need in AKI.
Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year
FORT LAUDERDALE, FL / ACCESS Newswire / April 6, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) ("Sunshine Biopharma" or the "Company"), a pharmaceutical company offering and developing life‑saving medicines across oncology, antivirals, and other key therapeutic areas, today announced the filing of its Annual Report on Form 10‑K for the fiscal year ended December 31, 2025.
MDCE's Snapshot Recipes App Scales Marketing Strategy Beyond Initial Podcast Deals with Expanded iHeart Campaign
New iHeart podcast campaign builds on previously announced shows, targeting over 1 million additional impressions across dozens of top-tier podcast programs.